VESO Vikan has long experience with design and conduct of sea lice trials.
Testing of in-feed drugs designed to reduce sea lice numbers is one of VESO Vikan's main priorities. Bioassays for examining the sensitivity against sea lice drugs based on population data have also been performed at our facility for years. Trials can be conducted according to Good Clinical Practice (GCP) guidelines. In addition to challenge trials and bioassays, other studies can be designed to evaluate the effect of treatments. VESO's internal research on sea lice involves a resistance selection study conducted in collaboration with several partners. Further information can be found in the menu to the right.
VESO has transferred its production of salmon lice copepodids, the infective stage of salmon lice, from Drøbak outside Oslo to a new production unit in the vicinity of the wet lab at VESO Vikan. Access to sea lice is now easier giving the closer proximity of the new production unit to aquaculture dense areas - with only few kilometres to fish farms and harvesting stations. Copepodids are moved to VESO Vikan and fish are infected for trials involving motile lice (pre-adult and adult stages) and non-motile lice (chalimus stage 1-4).
VESO possesses a vast experience in designing sea lice trials. The Bioassay method was developed at the Norwegian School of Veterinary Science by Dr Sigmund Sevatdal who is currently one of our project managers. For further information, please contact Sigmund Sevatdal or Christian Wallace.